📊 HURA Key Takeaways
Is HURA a Good Investment? Thesis Analysis
TuHURA is a pre-revenue biotech company in acute financial distress with zero sales, -$27.6M operating cash burn, and only $3.6M cash reserves (sufficient for ~6 weeks of operations). The company faces imminent liquidity crisis with current ratio of 0.78x and cannot cover short-term obligations with current assets, requiring immediate capital infusion to avoid insolvency.
Why Buy HURA? Key Strengths
- Minimal debt burden (Debt/Equity 0.00x, long-term debt only $265K)
- Positive stockholders' equity of $20.9M provides some asset backing
- Engagement indicated by 5 insider Form 4 filings in last 90 days
HURA Investment Risks to Consider
- Zero revenue and no clear path to profitability without successful product launch
- Critical liquidity crisis: current ratio 0.78x with $3.6M cash against $27.6M annual cash burn
- Deeply negative returns: ROE -143.6%, ROA -109.9%, suggesting severe capital inefficiency
- Unsustainable cash burn rate will necessitate dilutive financing or bankruptcy within months
Key Metrics to Watch
- Cash balance and runway (critical near-term survival metric)
- Revenue generation timeline from pipeline assets
- Capital raise announcements and dilution impact on equity
HURA Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
HURA Profitability Ratios
HURA vs Healthcare Sector
How TuHURA Biosciences, Inc./NV compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HURA Overvalued or Undervalued?
Based on fundamental analysis, TuHURA Biosciences, Inc./NV has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HURA Balance Sheet & Liquidity
HURA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: TuHURA Biosciences, Inc./NV's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.21 indicates the company is currently unprofitable.
HURA Growth Metrics (YoY)
HURA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$4.8M | $-0.14 |
| Q2 2025 | N/A | -$4.8M | $-0.21 |
| Q1 2025 | N/A | -$2.2M | $-0.15 |
| Q2 2013 | N/A | -$3.3K | N/A |
| Q2 2012 | N/A | -$10.9K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
HURA Capital Allocation
HURA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for TuHURA Biosciences, Inc./NV (CIK: 0001498382)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HURA
What is the AI rating for HURA?
TuHURA Biosciences, Inc./NV (HURA) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are HURA's key strengths?
Claude: Minimal debt burden (Debt/Equity 0.00x, long-term debt only $265K). Positive stockholders' equity of $20.9M provides some asset backing.
What are the risks of investing in HURA?
Claude: Zero revenue and no clear path to profitability without successful product launch. Critical liquidity crisis: current ratio 0.78x with $3.6M cash against $27.6M annual cash burn.
What is HURA's revenue and growth?
TuHURA Biosciences, Inc./NV reported revenue of $0.0.
Does HURA pay dividends?
TuHURA Biosciences, Inc./NV does not currently pay dividends.
Where can I find HURA SEC filings?
Official SEC filings for TuHURA Biosciences, Inc./NV (CIK: 0001498382) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HURA's EPS?
TuHURA Biosciences, Inc./NV has a diluted EPS of $-0.63.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HURA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, TuHURA Biosciences, Inc./NV has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HURA stock overvalued or undervalued?
Valuation metrics for HURA: ROE of -143.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy HURA stock in 2026?
Our dual AI analysis gives TuHURA Biosciences, Inc./NV a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HURA's free cash flow?
TuHURA Biosciences, Inc./NV's operating cash flow is $-27.6M, with capital expenditures of $76.1K.
How does HURA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -143.6% (avg: 15%), current ratio 0.78 (avg: 2).